- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Oliver Sartor discusses the management of synchronous, low-volume, metastatic hormone-sensitive prostate cancer. The presentation analyzes data from major trials like PEACE-1 and ARASENS while addressing the benefits of prostate radiation and acknowledging the complexity of real-world treatment decisions. Biographies: Oliver Sartor...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Nicholas James presents an analysis of triplet therapy in prostate cancer treatment, examining evidence from the PEACE-1, ARASENS, and ENZAMET trials. Through network meta-analysis, he explores the comparative effectiveness of different treatment combinations and proposes a framework based on disease characteristics. Biographies: N...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Sandy Srinivas examines the role of radiation therapy to the primary tumor in metastatic prostate cancer. The presentation questions whether overall survival should be the sole metric for evaluating interventions. Biographies: Sandy Srinivas, MD, Oncologist, Professor of Medicine (Oncology), Stanford University, Palo Alto, CA Relat...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Thomas Zilli discusses the evolving role of metastasis-directed therapy in treating metachronous low-volume or monosensitive prostate cancer, examining evidence from STOMP and ORIOLE trials that demonstrate its ability to postpone ADT use and improve outcomes with minimal toxicity. Biographies: Thomas Zilli, MD, Radiation Oncologis...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Michael Morris presents a critical examination of optimal imaging standards for metastatic hormone-sensitive prostate cancer. The presentation explores PSMA imaging's potential while acknowledging its complications such as flare phenomenon and PSMA downregulation. Biographies: Michael Morris, MD, Prostate Cancer Section Head, GU On...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), a panel discussion explores key questions in metastatic prostate cancer treatment. The panel debates mechanisms behind docetaxel's apparent harm in low-volume metachronous disease while emphasizing patient-centered decision-making, acknowledging that while ADT plus ARPI represents a clear standard of care, other treatment decisions...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal examines treatment de-escalation strategies in metastatic hormone-naive prostate cancer. He explores three main approaches: stopping ADT while continuing ARPI, stopping ARPI while maintaining ADT, and revisiting intermittent androgen deprivation therapy, and emphasizes the importance of clinical trials like the P6 p...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Mary-Ellen Taplin discusses the significance of PSA nadir values in metastatic hormone-sensitive prostate cancer treatment, reviewing data from SWOG 9346 and CHAARTED trials that establish PSA nadir as a prognostic indicator while emphasizing that unfavorable PSA decline doesn't necessarily indicate progression. Biographies: Mary-E...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Dana Rathkopf addresses the complex challenge of managing prostate cancer patients who show low-volume disease on conventional imaging but high-volume disease on next-generation PET imaging. The presentation explores evidence suggesting PET-only metastases may be more indolent than conventional imaging-visible disease. Biographies:...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Christopher Sweeney discusses strategies for managing early progression after combination therapy in prostate cancer. He emphasizes the importance of proper patient and tumor profiling while presenting ENZAMET trial data showing survival differences based on progression patterns. Biographies: Christopher Sweeney, MBBS, Professor of...
|
